A pharmaco-metabonomic study on chronic kidney disease and therapeutic effect of Ergone by UPLC-QTOF/HDMS

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Zhao, Ying Yong ^a   Chen, Hua ^a   Tian, Ting ^a   Chen, Dan Qian ^a   Bai, Xu ^c   Wei, Feng ^b   Dzeja, Petras ^d  

^a NORTHWEST UNIVERSITY   (China)

^b NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

^c Waters Technologies Shanghai Ltd   (China)

^d MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYBENZENESULFONIC ACID; 5 HYDROXYICOSATETRAENOIC ACID; ADENINE; ADRENIC ACID; ALDOSTERONE; ARACHIDONIC ACID; BASIC FIBROBLAST GROWTH FACTOR RECEPTOR; CALCIUM ION; CHOLESTEROL; COLLAGEN TYPE 1; COLLAGEN TYPE 3; CONNECTIVE TISSUE GROWTH FACTOR; CREATINE KINASE; CREATININE; DOCOSAHEXAENOIC ACID; ERGONE; ICOSAPENTAENOIC ACID; LINOLEIC ACID; NATURAL PRODUCT; NITROGEN; PHENYLALANINE; PHOSPHORUS; POLYUNSATURATED FATTY ACID; TRANSFORMING GROWTH FACTOR BETA1; TRIACYLGLYCEROL; TRYPTOPHAN; UNCLASSIFIED DRUG; UREA; URIC ACID; XANTHINE; BIOLOGICAL MARKER; ERGOSTEROL;

ALDOSTERONE BLOOD LEVEL; AMINO ACID METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOCHEMISTRY; BODY WEIGHT; CALCIUM BLOOD LEVEL; CHLORIDE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE COURSE; DOWN REGULATION; DRUG EFFECT; ENZYME BLOOD LEVEL; ERYTHROCYTE COUNT; FATTY ACID METABOLISM; HEMOGLOBIN BLOOD LEVEL; HISTOLOGY; KIDNEY MASS; LEUKOCYTE COUNT; MALE; MASS SPECTROMETRY; METABOLIC REGULATION; METABOLOMICS; NONHUMAN; PHOSPHATE BLOOD LEVEL; POTASSIUM BLOOD LEVEL; PROTEIN EXPRESSION; PURINE METABOLISM; RAT; RENAL PROTECTION; SODIUM BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY QUADRUPOLE TIME OF FLIGHT HIGH DEFINITION MASS SPECTROMETRY; URIC ACID BLOOD LEVEL; URINE VOLUME; ANALOGS AND DERIVATIVES; ANIMAL; DISCRIMINANT ANALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOHISTOCHEMISTRY; LEAST SQUARE ANALYSIS; METABOLISM; MULTIVARIATE ANALYSIS; PATHOLOGY; PROCEDURES; RENAL INSUFFICIENCY, CHRONIC; SPRAGUE DAWLEY RAT; STAINING;

ANIMALS; BIOMARKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DISCRIMINANT ANALYSIS; ERGOSTEROL; IMMUNOHISTOCHEMISTRY; LEAST-SQUARES ANALYSIS; MALE; MASS SPECTROMETRY; METABOLOMICS; MULTIVARIATE ANALYSIS; RATS, SPRAGUE-DAWLEY; RENAL INSUFFICIENCY, CHRONIC; STAINING AND LABELING; TRANSFORMING GROWTH FACTOR BETA1;

EID: 84919798332     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115467     Document Type: Article

References (56)

1. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351:1296-1305.
2. Kielstein JT, Zoccali C (2008) Asymmetric dimethylarginine: A novel marker of risk and a potential target for therapy in chronic kidney disease. Curr Opin Nephrol Hypertens 17:609-615.
3. Marescau B, Nagels G, Possemiers I, De Broe ME, Becaus I, et al. (1997) Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46:1024-1031.
4. Nicholson JK, Lindon JC (2008) Systems biology: metabonomics. Nature 455:1054-1056.
5. Zhao YY, Cheng XL, Vaziri ND, Liu S, Lin RC (2014) UPLC-based metabonomics applications for discovering biomarkers of diseases in clinical chemistry. Clin Biochem 47:16-26.
6. Chen H, Miao H, Feng YL, Zhao YY, Lin RC (2014) Metabolomics in dyslipidemia. Adv Clin Chem 66:101-119.
7. Zhao YY (2013) Metabolomics in chronic kidney disease. Clin Chim Acta 422:59-69.
8. Zhao YY, Lin RC (2014) Metabolomics in nephrotoxicity. Adv Clin Chem 65:69-89.
9. E application in disease biomarker discovery: The discoveries in proteomics to metabolomics. Chem-Biol Interact 215:7-16.
10. 1H NMR spectroscopy and liquid chromatography-mass spectrometry applied to the investigation of metabolic changes caused by gentamicin-induced nephrotoxicity in the rat. Biomarkers 10:173-187.
11. Zhao YY, Feng YL, Bai X, Tan XJ, Lin RC, et al. (2013) Ultra performance liquid chromatography-based metabonomic study of therapeutic effect of the surface layer of Poria cocos on adenine-induced chronic kidney disease provides new insight into anti-fibrosis mechanism. Plos One 8:e59617.
12. E. J Pharm Biomed Anal 81-82:202-209.
13. Zhao YY, Li HT, Feng YL, Bai X, Lin RC (2013) Urinary metabonomic study of the surface layer of poria cocos as an effective treatment for chronic renal injury in rats. J Ethnopharmacol 148:403-410.
14. Zhao YY, Zhao Y, Zhang YM, Lin RC, Sun WJ (2009) Qualitative and quantitative analysis of the diuretic component ergone in Polyporus umbellatus by HPLC with fluorescence detection and HPLCAPCI- MS/MS. Pharmazie 64:366-370.
15. Quang DN, Bach DD (2008) Ergosta-4, 6, 8(14), 22-tetraen-3-one from Vietnamese Xylaria sp. possessing inhibitory activity of nitric oxide production. Nat Prod Res 22:901-906.
16. Bok JW, Lermer L, Chilton J, Klingeman HG, Towers GH (1999) Antitumor sterols from the mycelia of Cordyceps sinensis. Phytochemistry 51:891-898.
17. Zhao YY (2013) Traditional uses, phytochemistry, pharmacology, pharmacokinetics and quality control of Polyporus umbellatus (Pers.) Fries: A review. J Ethnopharmacol 149:35-48.
18. Zhao YY, Xie RM, Chao X, Zhang YM, Lin RC, et al. (2009) Bioactivity-directed isolation, identification of diuretic compounds from Polyporus umbellatus. J Ethnopharmacol 126:184-187.
19. Zhao YY, Chao X, Zhang YM, Lin RC, Sun WJ (2010) Cytotoxic steroids from Polyporus umbellatus. Planta Med 76:1755-1758.
20. Zhao YY, Shen X, Chao X, Ho CC, Cheng XL, et al. (2011) Ergosta-4, 6, 8(14), 22-tetraen-3-one induces G2/M cell cycle arrest and apoptosis in human hepatocellular carcinoma HepG2 cells. Biochim Biophys Acta-Gen Subjects 1810:384-390.
21. Zhao YY, Zhang L, Mao JR, Cheng XH, Lin RC, et al. (2011) Ergosta-4, 6, 8(14), 22-tetraen-3-one isolated from Polyporus umbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. J Pharm Pharmacol 63:1581-1586.
22. Zhao YY, Qin XY, Cheng XL, Liu XY, Lin RC, et al. (2010) Rapid resolution liquid chromatography- mass spectrometry and high-performance liquid chromatography-fluorescence detection for metabolism and pharmacokinetic studies of ergosta-4, 6, 8(14), 22-tetraen-3-one. Anal Chim Acta 675:199-206.
23. Zhao YY, Qin XY, Zhang YM, Lin RC, Sun WJ, et al. (2010) Quantitative HPLC method and pharmacokinetic studies of ergosta-4, 6, 8(14), 22-tetraen-3-one, a natural product with diuretic activity from Polyporus umbellatus. Biomed Chromatogr 24:1120-1124.
24. Zhao YY, Chen XL, Zhang YM, Chao X, Lin RC, et al. (2010) A fast and sensitive HPLC-MS/MS analysis and preliminary pharmacokinetic characterization of ergone in rats. J Chromatogr B 878:29-33.
25. Zhao YY, Cheng XL, Wei F, Bai X, Lin RC (2012) Ultra performance liquid chromatography coupled with electrospray and atmospheric pressure chemical ionization-quadrupole time-of-flight mass spectrometry with novel mass spectrometryElevated Energy data collection technique: Determination and pharmacokinetics, tissue distribution and biliary excretion study of ergone in rat. J Sep Sci 35:1619- 1629.
26. Zhao YY, Cheng XL, Cui JH, Yan XR, Wei F, et al. (2014) Effect of ergosta-4, 6, 8(14), 22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: A serum metabonomics study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin Chim Acta 413:1438-1445.
27. Zhao YY, Shen X, Cheng XL, Wei F, Bai X, et al. (2012) Urinary metabonomics study on the protective effects of ergosta-4, 6, 8(14), 22-tetraen-3-one on chronic renal failure in rats using UPLC Q-TOF/MS and a novel MSE data collection technique. Process Biochem 47:1980-1987.
28. Wyngaarden JB, Dunn JT (1957) 8-Hydroxyadenine as the metabolic intermediate in the oxidation of adenine to 2, 8-dihydroxyadenine by xanthine oxidase. Arch Biochem Biophys 70:150-156.
29. Yokozawa T, Zheng PD, Oura H, Koizumi F (1986) Animal model of adenine-induced chronic renal failure in rats. Nephron 44:230-234.
30. Zhao YY, Cheng XL, Wei F, Bai X, Tan XJ, et al. (2013) Intrarenal metabolomic investigation of chronic kidney disease and its TGF-b1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. J Proteome Res 12:692-703.
31. Aminzadeh MA, Reisman SA, Vaziri ND, Khazaeli M, Yuan J, et al. (2014) The synthetic triterpenoid RTA dh404 (CDDO-dhTFEA) restores Nrf2 activity and attenuates oxidative stress, inflammation, and fibrosis in rats with chronic kidney disease. Xenobiotica 44:570-578.
32. Zhao YY, Shen XF, Cheng XL, Wei F, Bai X, et al. (2012) Application of faecal metabonomics on an experimental model of tubulointerstitial fibrosis by ultra performance liquid chromatography/highsensitivity mass spectrometry with MSE data collection technique. Biomarkers 17:721-729.
33. Zhao YY, Cheng XL, Wei F, Xiao XY, Sun WJ, et al. (2012) Serum metabonomics study of adenineinduced chronic renal failure rat by ultra performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. Biomarkers 17:48-55.
34. Zhao T, Zhang H, Zhao T, Zhang X, Lu J, et al. (2012) Intrarenal metabolomics reveals the association of local organic toxins with the progression of diabetic kidney disease. J Pharm Biomed Anal 60:32-43.
35. Rhee EP, Souza A, Farrell L, Pollak MR, Lewis GD, et al. (2010) Metabolite profiling identifies markers of uremia. J Am Soc Nephrol 21:1041-1051.
36. Kaori K, Yoshiharu I, Ryoko T, Atsuko E, Kenjiro M, et al. (2010) Metabolomic search for uremic toxins as indicators of the effect of an oral sorbent AST-120 by liquid chromatography/tandem mass spectrometry. J Chromatogr B 878:2997-3002.
37. Dyerberg J (1986) Linoleate-derived polyunsaturated fatty acids and prevention of atherosclerosis. Nutr Rev 44:125-134.
38. Nakamura N, Fujita T, Kumasaka R, Murakami R, Shimada M, et al. (2008) Serum lipid profile and plasma fatty acid composition in hemodialysis patients-comparison with chronic kidney disease patients. In Vivo 22:609-612.
39. James MJ, Gibson RA, Cleland LG (2000) Dietary polyunsaturated fatty acids and inflammatory mediator production. Am J Clin Nutr 71:S343-48.
40. Calder PC (2003) N-3 polyunsaturated fatty acids and inflammation: from molecular biology to the clinic. Lipids 38:343-352.
41. Shidfar F, Keshavarz A, Hosseyni S, Ameri A, Yarahmadi S (2008) Effects of omega-3 fatty acid supplements on serum lipids, apolipoproteins and malondialdehyde in type 2 diabetes patients. East Mediterran Health J 14:305-315.
42. 2.5. Environ Health Perspect 116:1237-1242.
43. Nenseter MS, Drevon CA (1996) Dietary polyunsaturates and peroxidation of low density lipoproteins. Curr Opin Lipidol 7:8-13.
44. Maritim AC, Sanders RA, Watkins JB (2003) Diabetes, oxidative stress, and antioxidants: A review. J Biochem Mol Toxicol 17:24-38.
45. Calder PC (2006) N-3 polyunsaturated fatty acids, inflammation, and inflammatory diseases. Am J Clin Nutr 833:S1505-1519.
46. Priante G, Musacchio E, Valvason C, Baggio B (2009) EPA and DHA suppress AngII- and arachidonic acid-induced expression of profibrotic genes in human mesangial cells. J Nephrol 22:137-143.
47. Wu IW, Hsu KH, Lee CC, Sun CY, Hsu HJ, et al. (2011) p-Cresyl sulphate and indoxyl sulphate predict progression of chronic kidney disease. Nephrol Dial Transplant 26:938-947.
48. Vanholder R, De Smet R, Lameire N (2001) Protein-bound uremic solutes: The forgotten toxins. Kidney Int 78:S266-270.
49. Tumur Z, Shimizu H, Enomoto A, Miyazaki H, Niwa T (2010) Indoxyl sulfate upregulates expression of ICAM-1 and MCP-1 by oxidative stress-induced NF-kappaB activation. Am J Nephrol 31:435-441.
50. Miyazaki T, Ise M, Seo H, Niwa T (1997) Indoxyl sulfate increases the gene expressions of TGF-beta 1, TIMP-1 and pro-alpha 1(I) collagen in uremic rat kidneys. Kidney Int 62:S15-S22.
51. Iida S, Kohno K, Yoshimura J, Ueda S, Usui M, et al. (2006) Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure. Clin Exp Nephrol 10:262-267.
52. Kim TH, Ahn MY, Lim HJ, Lee YJ, Shin YJ, et al. (2012) Evaluation of metabolomic profiling against renal toxicity in Sprague-Dawley rats treated with melamine and cyanuric acid. Arch Toxicol 86:1885- 1897.
53. Zhao YY, Liu J, Cheng XL, Bai X, Lin RC (2012) Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin Chim Acta 413:642-649.
54. Ma C, Bi K, Su D, Ji W, Zhang M, et al. (2010) Serum and kidney metabolic changes of rat nephrotoxicity induced by Morning Glory Seed. Food Chem Toxicol 48:2988-2993.
55. Jia LW, Chen J, Yin PY, Lu X, Xu GW (2008) Serum metabonomics study of chronic renal failure by ultra performance liquid chromatography coupled with Q-TOF mass spectrometry. Metabolomics 4:183- 199.
56. Sui W, Li L, Che W, Guimai Z, Chen J, et al. (2012) A proton nuclear magnetic resonance-based metabonomics study of metabolic profiling in immunoglobulin a nephropathy. Clinics (Sao Paulo) 67:363-373.